5 Versus 10 Units of Insulin in Hyperkalemia Management
Launched by OMAN MEDICAL SPECIALITY BOARD · Sep 11, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective two different doses of insulin are in treating hyperkalemia, which is a condition where there is too much potassium in the blood. The researchers want to find out whether giving patients 5 units or 10 units of intravenous insulin will better lower potassium levels over a period of 2 hours.
To be eligible for this study, participants need to be adults aged 18 or older who have high potassium levels of 5.5 mEq/L or more. However, certain conditions like heart failure, very high or low blood sugar levels, pregnancy, and other serious health issues may prevent someone from participating. If you join the study, you can expect to receive either the 5-unit or 10-unit dose of insulin and have your potassium levels checked after two hours to see how well the treatment worked. This trial is important because it could help doctors decide the best way to manage hyperkalemia and improve patient care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hyperkalemia patients with lab potassium levels equal to or more than 5.5 mEq/L (≥ 5.5 mEq/L)+.
- • Adult: age 18 years or more.
- • Agreed to participate in the study.
- • If an investigator decides to start anti-hyperkalemia medications based on the VBG/ABG patient can be enrolled but if the main laboratory value is less than 5.5 mEq/L patients will be excluded
- Exclusion Criteria:
- • Cardiac arrest
- • Hyperglycemia with random blood sugar 20 mmol/L (13) or with acute diabetic complications like Diabetic Ketoacidosis / Hyperosmolar Hyperglycemic State.
- • Hypoglycemia with random blood sugar (RBS) ≤ 3.89 mmol/l in Diabetic patients and less than 3 mmol/l in non-diabetic patients.
- • Allergies for any medication in the protocol.
- • Pregnancy.
- • Hemolyzed potassium level as reported by the main lab.
- • Hemolysis, Tumor lysis syndrome, or Rhabdomyolysis due to the ongoing release of potassium.
- • Acidosis with a pH less than 7.1 will require Sodium bicarbonate (NaHO3).
- • A patient who will need urgent Furosemide (Lasix), and or dialysis during the study period of 2 hours.
- • Refused to participate.
About Oman Medical Speciality Board
The Oman Medical Specialty Board (OMSB) is a leading regulatory and educational authority dedicated to advancing medical education and healthcare standards in Oman. Established to enhance the quality of medical training and practice, OMSB plays a pivotal role in overseeing clinical trials, ensuring they adhere to rigorous ethical and scientific standards. By fostering collaboration between healthcare professionals, researchers, and institutions, OMSB aims to promote evidence-based medicine and drive innovation in clinical practices, ultimately improving patient outcomes and healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seeb, Muscat, Oman
Patients applied
Trial Officials
Suad Al-Abri
Principal Investigator
Sultan Qaboos University hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported